Macrogenics Inc (NAS:MGNX)
$ 4.36 0.25 (6.07%) Market Cap: 273.08 Mil Enterprise Value: 122.86 Mil PE Ratio: 0 PB Ratio: 2.57 GF Score: 60/100

MacroGenics Inc at Citi BioPharma Conference (Virtual) Transcript

Sep 09, 2021 / 05:25PM GMT
Release Date Price: $23 (+8.90%)
Yigal Dov Nochomovitz
Citigroup Inc., Research Division - Director

Okay. Great. Welcome, everyone, to the afternoon session, Large Molecule Drugs for Oncology -- Framing the Tip of the Spear for Novel Antibodies and Protein Therapeutics. I'm Yigal Nochomovitz, one of the biotech analysts here at Citi. It's my pleasure to have with me the leaders of 5 protein antibody companies, apart from Harpoon Therapeutics, Jerry McMahon, President and CEO; from MacroGenics, Scott Koenig, also President and CEO; from Merus, Bill Lundberg, the CEO; from Shattuck Labs, Taylor Schreiber, the CEO; and from Zymeworks, Ali Tehrani, President and CEO. So welcome, gentlemen, to the program, a lot to discuss today.

But as a starting point, perhaps you could just give a brief introduction to your company. And in doing so, cover what are the strengths and differentiating qualities of your antibody or protein therapeutic platforms. Maybe we could start with Scott.

Scott Koenig
MacroGenics, Inc. - CEO, President & Director

Thank you, Yigal, and it's a real pleasure to

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot